If heard correctly, two comments in passing from the presentation struck me: SAVR trial is back on with a seventh patient doing well with the study's conclusion expected this year and AVR has had frequent discussions with the FDA about its proposed TAVR study. This appears to underline the significant and rapid progress towards commercialisation, with execution risk dominating product risk now. Product risk fast diminishing as each supporting study (clinical, animal and bench) attests. 7/7 patient success for the DurAVR valve in a SAVR procedure with the AVR valve achieving pre-disease function is amazing, especially given the performance of competitor valves. SAVR market is a multibillion market.
No mention of any ongoing discussions with other players in TAVR or SAVR markets.
Wayne presenting at the ASX small and mid cap conference 16th March, page-14
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.91 |
Change
-0.090(0.90%) |
Mkt cap ! $209.4M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.00 | $9.65 | $70.76K | 7.202K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $9.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.91 | 475 | 2 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |